Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & Administrative
Others
Ratios

AC Immune (ACIU) Operating Expenses (2016 - 2025)

Historic Operating Expenses for AC Immune (ACIU) over the last 12 years, with Q3 2025 value amounting to -$21.4 million.

  • AC Immune's Operating Expenses fell 170.03% to -$21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.6 million, marking a year-over-year decrease of 331.94%. This contributed to the annual value of -$91.0 million for FY2024, which is 1792.24% down from last year.
  • Per AC Immune's latest filing, its Operating Expenses stood at -$21.4 million for Q3 2025, which was down 170.03% from -$25.0 million recorded in Q2 2025.
  • AC Immune's 5-year Operating Expenses high stood at -$17.5 million for Q3 2023, and its period low was -$25.0 million during Q2 2025.
  • For the 5-year period, AC Immune's Operating Expenses averaged around -$21.1 million, with its median value being -$20.7 million (2023).
  • As far as peak fluctuations go, AC Immune's Operating Expenses skyrocketed by 2146.12% in 2022, and later plummeted by 2626.88% in 2024.
  • Quarter analysis of 5 years shows AC Immune's Operating Expenses stood at -$24.7 million in 2021, then rose by 21.46% to -$19.4 million in 2022, then decreased by 6.54% to -$20.7 million in 2023, then dropped by 9.06% to -$22.6 million in 2024, then grew by 5.18% to -$21.4 million in 2025.
  • Its Operating Expenses stands at -$21.4 million for Q3 2025, versus -$25.0 million for Q2 2025 and -$22.6 million for Q1 2025.